<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136353</url>
  </required_header>
  <id_info>
    <org_study_id>ANZUP1801</org_study_id>
    <secondary_id>U1111-1239-0771</secondary_id>
    <nct_id>NCT04136353</nct_id>
  </id_info>
  <brief_title>Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate</brief_title>
  <acronym>DASL-HiCaP</acronym>
  <official_title>DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian and New Zealand Urogenital and Prostate Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of darolutamide as part of
      adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone
      analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high
      risk of recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Evidence of metastases includes findings on WBBS or CT or MRI (as reported by the site investigator) that are either characteristic of metastatic prostate cancer, and/or confirmed by other test results e.g. cytology or histopathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA-progression free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>For participants who receive definitive radiotherapy (i.e. without radical prostatectomy), PSA progression is defined by the Phoenix criteria (requires confirmation by a repeat PSA performed at least 3 weeks later). For participants who have undergone a radical prostatectomy, an increase in PSA of &gt;0.2 ng/mL above the nadir would be considered PSA progression (requires confirmation by a repeat PSA performed at least 3 weeks later).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent hormonal therapy</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration-resistance</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Defined according to the PCWG3 criteria. If a participant has radiographic progression without serological progression, this will also be deemed castration resistant prostate cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (CTCAE V5.0)</measure>
    <time_frame>Approximately 12-weekly for 2 years from randomisation until 30 days after the last dose of study treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>EORTC Core Quality of Life Questionnaire (QLQC-30). Importance of quality of life issues are assessed using a four-point scale (1 = not at all, 4 = very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>EORTC Quality of Life Questionnaire for Prostate Cancer (PR-25). Importance of quality of life issues are assessed using a four-point scale (1 = not at all, 4 = very much)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Euroqol 5 item preference-based measure of health (EQ-5D-5L), comprising 5 questions with a score from 1 to 5 each and a visual analogue scale from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of cancer recurrence</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Using the Fear of Cancer Recurrence Inventory (FCRI), a 42-item questionnaire with scores of 0 (never/not at all) - 4 (all the time/a great deal) for each.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Darolutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.
All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.
All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darolutamide</intervention_name>
    <description>2 x 300mg oral tablets twice daily for 96 weeks</description>
    <arm_group_label>Darolutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>2 oral tablets twice daily for 96 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luteinizing Hormone-Releasing Hormone Analog</intervention_name>
    <description>All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.</description>
    <arm_group_label>Darolutamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiotherapy</intervention_name>
    <description>All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.</description>
    <arm_group_label>Darolutamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men aged 18 years and older, with pathological diagnosis of adenocarcinoma of the
             prostate

          2. EITHER planned for primary RT and judged to be at very high risk for recurrence based
             on any of the following:

               -  Grade Group 5, OR

               -  Grade Group 4 AND one or more of the following: clinical T2b-4 OR MRI with
                  seminal vesicle invasion OR extracapsular extension OR PSA &gt; 20ng/mL, OR

               -  Pelvic nodal involvement (involvement of lymph nodes (LNs) at or below the
                  bifurcation of the common iliac arteries) defined radiologically as greater than
                  10mm on short axis using standard CT or MRI, or pathologically confirmed (PSMA
                  PET alone is not considered enough if &lt; 10mm)

             OR Post-radical prostatectomy ≤ 365 days prior to randomisation and planned for RT
             with persistent PSA (≥ 0.1 ng/mL which has not fallen on two occasions at least one
             week apart) or rising PSA (PSA &gt; 0.1 ng/mL and rising on two occasions at least one
             week apart) judged to be at very high risk for recurrence based on any of the
             following:

               -  Grade Group 5, OR

               -  Grade Group 4 AND pT3a or higher, OR

               -  Pelvic nodal involvement (involvement of LNs at or below the bifurcation of the
                  common iliac arteries) defined radiologically as greater than 10mm on short axis
                  using standard CT or MRI, or pathologically confirmed (PSMA PET alone is not
                  considered enough if ≤ 10mm)

          3. Adequate bone marrow function: Haemoglobin ≥ 100g/L, white cell count (WCC) ≥
             4.0x10^9/L, absolute neutrophil count (ANC) ≥ 1.5x10^9/L and platelets &gt; 100 x 10^9/L

          4. Adequate liver function: alanine aminotransferase (ALT) &lt; 2 x upper limit of normal
             (ULN) and total bilirubin &lt; 1.5 x ULN, (or if total bilirubin is between 1.5 - 2 x
             ULN, they must have a normal conjugated bilirubin)

          5. Adequate renal function: calculated creatinine clearance &gt; 30 mL/min (Cockroft-Gault)

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

          7. Study treatment both planned and able to start within 7 days after randomisation

          8. Willing to complete health-related quality of life (HRQL) questionnaires UNLESS is
             unable to complete because of literacy or limited vision

          9. Willing and able to comply with all study requirements, including standard of care
             treatment such as EBRT, timing and/or nature of required assessments

         10. Signed, written informed consent

             Exclusion Criteria:

         11. Prostate cancer with predominant non-adenocarcinoma features (sarcomatoid or spindle
             cell or neuroendocrine small cell or squamous cell components or other
             non-adenocarcinoma)

         12. Involvement of LNs by conventional CT imaging superior to the common iliac artery
             bifurcation, and/or outside the pelvis (distant LNs). LN involvement is defined by
             histopathological confirmation, or by a short axis measurement &gt;10mm on standard
             imaging (CT or MRI, but not PET).

         13. Evidence of metastatic disease per RECIST criteria: the minimum imaging required is a
             CT and/or MRI of the abdomen and pelvis, and a whole body radioisotope bone scan
             (WBBS). If equivocal bone scan, follow-up plain films are required to show NO evidence
             of cancer if not covered by CT/MRI. If PSMA PET shows disease beyond the pelvic LN not
             seen on conventional imaging per RECIST, the patient is still eligible.

         14. PSA &gt; 100 ng/mL

         15. Any prior use of new generation potent androgen receptor inhibition (abiraterone,
             enzalutamide, apalutamide, darolutamide or similar agents).

         16. Prior ADT except the following, which are allowed:

               -  Prior androgen deprivation commenced within 90 days prior to randomisation as
                  long as it is limited to: (i) LHRHA, or (ii) low potency nonsteroidal
                  antiandrogen (NSAA) (e.g bicalutamide, flutamide, nilutamide);

               -  Any prior use of 5-alpha reductase inhibitor

         17. Bilateral orchidectomy

         18. Prior pelvic brachytherapy or other radiotherapy that would result in an overlap of
             radiotherapy fields that would preclude the required RT

         19. History of

               -  Loss of consciousness or transient ischemic attack within 3 months prior to
                  randomisation, or

               -  Significant cardiovascular disease within 3 months prior to randomisation:
                  including myocardial infarction, unstable angina, congestive heart failure (NYHA
                  grade II or greater), ongoing arrhythmias of Grade &gt; 2 (CTCAE v5.0),
                  thromboembolic events (e.g. deep vein thrombosis, pulmonary embolism). Chronic
                  stable atrial fibrillation on stable anticoagulant therapy is allowed.

         20. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption or tolerance of darolutamide, including difficulty swallowing tablets

         21. History of another malignancy within 5 years prior to randomisation except for those
             malignancies treated with curative intent with a predicted risk of relapse of less
             than 10% including but not limited to non-melanoma carcinoma of the skin; or
             adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e. Tis,
             Ta and low grade T1 tumours). All such cases are to be discussed with study chairs and
             rationale for decision documented.

         22. Concurrent illness, including severe infection that might jeopardise the ability of
             the participant to undergo the procedures outlined in this protocol with reasonable
             safety (HIV infection is not an exclusion criterion if it is controlled with
             anti-retroviral drugs that are unaffected by concomitant darolutamide)

         23. Presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule,
             including alcohol dependence or drug abuse

         24. Patients who are sexually active and not willing/able to use medically acceptable
             forms of barrier contraception

         25. Participation in other clinical trials of investigational agents for the treatment of
             prostate cancer or other diseases

         26. Major surgery within 21 days prior to randomisation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Sweeney</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute and Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamim Niazi</last_name>
    <role>Study Chair</role>
    <affiliation>Jewish General Hospital and McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DASL Trial Coordinator</last_name>
    <phone>61295625000</phone>
    <email>dasl@ctc.usyd.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Border Medical Oncology Research Unit</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher Steer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Craig Kukard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenesisCare Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2290</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jarad Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jarad Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Public Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anthony Joshua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Colin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leily Crezaei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurence Krieger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Adventist Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amy Teh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark Sidhom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nadine Beydoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Campbelltown hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Felicia Roncolato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Senthikumar Gandhidasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ROPART</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Pryor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Phillip Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Centre</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Khoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Pryor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francis Parnis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre - Bendigo Campus</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Neetu Tejani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre (Moorabbin Campus)</name>
      <address>
        <city>Bentleigh East</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Scott Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Lim Joon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Scott Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeremy Millar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Hospital</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Violet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6143</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tee Sin Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Suki Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chakiath Jose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ben Hindson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4442</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zhun Zeat Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinically localised prostate cancer</keyword>
  <keyword>very high risk</keyword>
  <keyword>darolutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

